ADHD Therapeutics: A Global Strategic Business Report
San Jose, CA (Vocus) June 4, 2010
Attention Deficit Hyperactivity Disorder (ADHD), a common neurodevelopmental psychiatric disorder, affects an estimated 5% of the worldwide children in the age group of 5-17 years. Genetics play a major role in its propagation, with almost three-fourth of the diagnosed patients having some history of ADHD in their families. Currently, stimulant medication used in conjunction with behavioral interventions is considered the best treatment option for ADHD patients.
Existing ADHD drugs are only successful in fulfilling the therapeutic needs of ADHD treatment, with issues relating to complete cure, efficacy and safety remaining unresolved. The existing drugs work by reducing the remission rates, increasing the disorder’s relapse rates, and treating the symptoms rather than the disorder itself. Consequently, the potential for any pipeline drug strong in safety as well as efficacy is huge, indicating greater chances of the drug expanding the segment revenues and penetrating geographic markets that are yet unexplored.
Global market for ADHD drugs is severely constrained by the lack of awareness about the disorder, even in developed countries such as the UK, Germany and Japan. Lack of consensus on common diagnostic criteria, use of stimulants as medicines, side effects from medicines, and ambiguity about the causes of the disorder are some of the major roadblocks for the growth, especially in non-US markets. Introduction of generics is also likely to shake-up the market, fostering volume expansion due to lowering of costs.
The United States represents the predominant market for ADHD drugs, as stated by the new market research report on ADHD Therapeutics market. By 2012, the market is forecast to reach US$3.3 billion, with growth anticipated largely from the adult ADHD segment, which now comprises the major target for most companies. The low diagnosis rates in adult population present significant opportunities for players in the ADHD drugs market. However, lack of consensus on the diagnostic criteria, the social stigma attached with a psychiatric disorder, and lack of awareness all comprise the major impediments.
The global ADHD drugs landscape is heavily skewed towards the US market. Consequently, companies with strong positions in the domestic market are deemed as major forces in the global ADHD arena. Shire Plc, Johnson & Johnson and Eli Lilly & Company are the leading players in the global ADHD market. Shire Pharmaceuticals is the largest player in the ADHD market with its strong portfolio of drugs including Adderall XR, Vyvanse, Daytrana and Intuniv.
The report titled “ADHD Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, product introductions, and recent industry activity. The study analyzes market data and analytics in terms of annual revenues for regions including The United States and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/